A Phase 2 interventional study of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine and ACYW135 Meningococcal Polysaccharide Vaccine in Meningococcal Meningitis, sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 3 Months to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-29.
Sponsored by Aimei Vacin BioPharm (Zhejiang) Co., Ltd. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Meningitis, Meningococcal with a site in China — 5 open to participants now, 8 under way, 5 of them phase 3. Meningitis, Meningococcal · China.
Among the 19 studies in Meningitis, Meningococcal with a site in China, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is one of 2 in phase 2, and was the 12th registered.
125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.
Browse Meningitis, Meningococcal studies →5 of the 19 studies in Meningitis, Meningococcal with a site in China are open now. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–5 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 6 mo–11 mo · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 12 mo–23 mo · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 2 mo–6 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 3 Months to 15 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 3 10 · Phase 4 2
First in 2015; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 1,200 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.
Median enrollment 840 across the 19 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 19 have an industry lead sponsor. The 8 most frequent:
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Aimei Vacin BioPharm (Zhejiang) Co., Ltd. has 1 study filed under Meningitis, Meningococcal — fewer than ten, so there is no comparison to draw.
4 of the studies in Meningitis, Meningococcal with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07505888Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years | 2026-11 |
| NCT07505836Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months | 2027-01 |
| NCT07505823Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months | 2027-04 |
| NCT07505810Phase 3Sinovac Biotech Co., LtdPhase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 19 studies in Meningitis, Meningococcal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to explore the safety and immunogenicity of the experimental vaccine compared with the control vaccines. It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination; the 2-15 year-old group will have one dose vaccination.
The purpose of this study was to evaluate the safety and immunogenicity of the experimental vaccine(ACYW135 Meningococcal Polysaccharide Conjugate Vaccine) compared with the control vaccines(ACYW135 Meningococcal Polysaccharide Conjugate Vaccine and ACYW135 Meningococcal Polysaccharide Vaccine). It is planed to enroll a total of 1,200 subjects, including 300 subjects in each of the 3-5 months old, 6-11 months old, 12-23 months old and 2-15 years old groups, who will be randomly assigned to the trial in a 1:1 ratio to study group or control group. The 3-5 month-old group will have three doses vaccination at 0, 1 and 2 month, and a booster dose at 12 months of age; the 6-11month-old and 12-23 month-old groups will each have total two doses vaccination(at month 0, 1 or at month 0, 3); the 2-15 year-old group will have one dose vaccination. The immunogenicity and immune persistence will be evaluated by rabbit complement serum bactericidal assay.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
3\~5 months old:
6\~23 months old:
2\~15 years old:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2\~15 years old participants who vaccinated by experimental vaccine
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
2\~15 years old participants who vaccinated by control vaccine 2
Biological: ACYW135 Meningococcal Polysaccharide Vaccine
6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 1
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 1
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
6\~23 months old participants who vaccinated by experimental vaccine at month 0 and 3
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
6\~23 months old participants who vaccinated by control vaccine 1 at month 0 and 3
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
3\~5 months old participants who vaccinated by experimental vaccine at month 0, 1, 2 for primary vaccination, and vaccinated by experimental vaccine at 12-month old for booster vaccination
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
3\~5 months old participants who vaccinated by control vaccine 1 at month 0, 1, 2 for primary vaccination, and vaccinated by control vaccine at 12-month old for booster vaccination
Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
ACYW135 Meningococcal Polysaccharide Conjugate Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135 and conjugated protein CRM197.
ACYW135 Meningococcal Polysaccharide Vaccine was produced by meningococcal polysaccharide from group A, C, Y, W135.
Immunogenicity 1
To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 3\~5 months old participants after primary vaccination
Time frame: 30 days after primary vaccination
Immunogenicity 2
To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 6\~23 months old participants after two doses vaccination
Time frame: 30 days after two doses vaccination
Immunogenicity 3
To evaluate the positive conversion rate and geometric mean titer (GMT) of meningococcal serum bactericidal activity (rSBA) antibodies for meningococcal groups A, C, Y, and W135 at 30 days in 2\~15 years old participants after one dose vaccination
Time frame: 30 days after one dose vaccination
Safety 1
The incidence of adverse events (AEs)/vaccination-related AEs on days 0 to 30 after each dose of immunization for subjects in each age group
Time frame: 30 days after each dose vaccination
Immunogenicity 4
To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8), ratio of antibody titer ≥1:128, geometric mean growth factor (GMFI) in 3\~5 months old participants after primary vaccination
Time frame: 30 days after booster vaccination
Immunogenicity 5
To evaluate the serum bactericidal activity (rSBA) antibody GMT, positivity rate and rate of antibody titer ≥1:128 subjects in 3\~5 months old participants before booster vaccination
Time frame: Before booster vaccination
Immunogenicity 6
To evaluate the serum bactericidal activity (rSBA) antibody positive conversion rate, GMT, GMFI, positivity rate, and rate of antibody titer≥ 1:128 ratio in 3\~5 months old participants after booster vaccination
Time frame: 30 days after booster vaccination
Immunogenicity 7
To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8), ratio of antibody titer ≥1:128, geometric mean growth factor (GMFI) in 6\~23 months old participants after two doses vaccination
Time frame: 30 days after booster vaccination
Immunogenicity 8
To evaluate the positive rate of serum bactericidal activity (rSBA) antibodies against meningococcal groups A, C, Y and W135 (ratio of antibody titers ≥1:8) and ratio of antibody titer ≥1:128 in 6\~23 months old participants after vaccination
Time frame: 30 days after vaccination
Immune persistence 1
To evaluate the serum bactericidal activity (rSBA) antibody positivity rate, rate of antibody titer ≥1:128 and GMT in 3\~5 months old participants after booster vaccination
Time frame: 6 months after booster vaccination
Immune persistence 2
To evaluate the serum bactericidal activity (rSBA) antibody positivity rate, rate of antibody titer ≥1:128 and GMT in 6\~23 months old participants after two doses vaccination
Time frame: 6 months, 12 months
Safety 2
AEs/vaccination-related AEs are divided into doses, severity, vaccination site and non-vaccination site, and system organs (SOC) classification and incidence of each preferred term (PT) symptom after each dose vaccination
Time frame: 30 days after each dose vaccination
Safety 3
The occurrence of serious adverse events (SAE) in each group of subjects aged 3 to 5 months from the first dose vaccination to 6 months after primary vaccination and within 30 days after booster vaccination
Time frame: 6 months after primary vaccination and 30 days after booster vaccination
Safety 4
The occurrence of serious adverse events (SAE) in each group of subjects aged 2\~15 years and 6\~23 months from the first dose vaccination to 6 months after all doses vaccination
Time frame: 6 months after all doses vaccination
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2024; primary completion for Jun 2024, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.